Our results suggest that although cisplatin and paclitaxel exert their killing effects on ovarian cancer cells, they simultaneously induce the emergence of a subpopulation of cancer cells with activated Akt/c/EBPβ/COL11A1 signalling, which confers chemoresistance. The gene discussed is AKT1; the disease is ovarian cancer.